Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From The National Marrow Donor Program

Dr. Auayporn Nademanee of City of Hope leads study showing efficacy of

novel therapy

Nov 08, 2007, 00:00 ET from StemCyte, Inc.

    ARCADIA, Calif. and DUARTE, Calif., Nov. 8 /PRNewswire/ -- The National
 Marrow Donor Program (NMDP) has selected an abstract written by Dr.
 Auayporn Nademanee, physician and professor in the Division of Hematology &
 Hematopoietic Cell Transplantation at City of Hope, and Dr. Robert Chow,
 Founder and Global Medical Director for StemCyte, as one of four best
 abstracts at its annual Council Meeting in Minneapolis, MN. The abstract,
 "Adult Patients with Malignancies Transplanted with Plasma Depleted Cord
 Blood (PD CB) -- A Retrospective Audited Analysis of 107 Patients" was
 presented by Dr. Nademanee at the NMDP Council Meeting and has several
 other co-authors.
     The abstract describes the safety and effectiveness of transplanting
 single or double plasma-depleted umbilical cord blood units into adult
 patients with cancers of the blood. All of the plasma-depleted cord blood
 was processed and shipped from the StemCyte International Cord Blood Center
 in Arcadia, CA. Dr. Nademanee says, "Patients treated with plasma-depleted
 cord blood demonstrated excellent outcomes in terms of overall survival,
 transplant-related mortality, and the absence of complications such as
 graft-versus-host disease. We believe that plasma-depleted cord blood will
 continue to be an effective treatment for patients with leukemia, lymphoma,
 and other malignant indications."
     Dr. Chow says, "We thank NMDP for selecting ours as one of their Best
 Abstracts. We are heartened to see the outstanding patient outcomes using
 StemCyte's plasma-depleted cord blood products. However, none of these
 results would be possible without the tremendous care given to patients by
 physicians like Dr. Nademanee at City of Hope. We are gratified to have the
 support and confidence of physicians at City of Hope and other leading
 transplant centers around the world." StemCyte has shipped cord blood
 products to over 140 of the leading transplant centers in 32 countries
 around the world.
     About StemCyte
     StemCyte, Inc. operates as both an international umbilical stem cell
 storage bank and a therapeutics company. Stem cells are used to replace or
 initiate the production of other cells that are damaged or missing due to
 disease. StemCyte collects, processes and banks umbilical cord blood
 ("UCB") stem cells to be used as therapeutic treatments. The Company
 currently operates UCB storage banks in California and Taiwan and is
 expanding its locations into other regions around the globe. In addition,
 the Company is pursuing collaborations with a number of leading stem cell
 researchers to improve and expand the treatment opportunities using stem
     UCB stem cells are a non-controversial and readily available source of
 stem cells, harvested from umbilical cords that would otherwise be
 discarded. To date, UCB stem cells have been used in approximately 8,000
 transplants worldwide and have successfully treated certain cancers (e.g.,
 leukemia, lymphoma and myeloma), blood disorders (e.g., thalassemia, sickle
 cell anemia and Fanconi anemia) and immune deficiency diseases. StemCyte
 and its scientific founder have developed proprietary processes to ensure
 that the least number of stem cells are lost post-collection and post-thaw.
 Studies have shown that successful patient engraftment and survival outcome
 are directly correlated to the number of stem cells provided. StemCyte's
 stem cells are currently being used to treat three to four patients per
 week and the Company recently released its 600th cord blood stem cell
 shipment for transplant. With an inventory of over 25,000 units, the
 Company's stem cell banks represent one of the largest and most ethnically
 diverse sources of unrelated (allogeneic) UCB stem cells.
     StemCyte's therapeutic activities involve expanding the use of UCB stem
 cells in indications where stem cells are already an FDA-approved therapy,
 validating the engraftment and survival benefits of its proprietary stem
 cell processing technology and participating in clinical trials for new
 transplant indications. New indications include thalassemia, a devastating
 red blood cell deficiency diagnosed in over 150,000 babies each year with
 severe forms of the disease, and non-blood-based disorders, including
 neurodegenerative diseases.
     StemCyte has received accreditation from the American Association of
 Blood Banks (AABB), the National Marrow Donor Program (NMDP), the College
 of American Pathologists (CAP), and Foundation for the Accreditation of
 Cellular Therapy (FACT) for allogeneic donations and has the only cord
 blood bank in the world accredited by FACT for autologous donations.
 StemCyte is one of only six banks to have been selected to participate in
 the C.W. Bill Young Cell Transplantation Program under the initial $79
 million authorized by Congress in the Stem Cell Therapeutic and Research
 Act of 2005.
     StemCyte is privately-held. Visit for more
     About City of Hope
     City of Hope is a leading research and treatment center for cancer,
 diabetes and other life-threatening diseases. Designated as a Comprehensive
 Cancer Center, the highest honor bestowed by the National Cancer Institute,
 and a founding member of the National Comprehensive Cancer Network, City of
 Hope's research and treatment protocols advance care throughout the nation.
 City of Hope is located in Duarte, Calif., just northeast of Los Angeles,
 and is ranked as one of "America's Best Hospitals" in cancer and urology by
 U.S.News & World Report. Founded in 1913, City of Hope is a pioneer in the
 fields of bone marrow transplantation and genetics. For more information,
     David Carmel
     StemCyte, Inc.

SOURCE StemCyte, Inc.